Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (September 25th Preview)
-
FDA approvals in oncology and rare disease
The FDA approved Elevar Therapeutics’ Lyrfigtu (lirafugratinib) for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement, based on the multicenter REFOCUS phase 1/2 trial. The study reported a 46% objective response rate with a median duration of response of 11.8 months. On the rare-disease front, FDA approved Mirum Pharmaceuticals’ zilurgisertib, branded Atebrioz, as the third treatment for ultra-rare soft tissue disease. The ALK2-blocking therapy targets patients with a genetic disorder that drives progressive muscle and connective tissue turning into bone. Together, the approvals reinforce regulators’ continued focus on biomarker-selected oncology and ultra-rare genetic pathways, while highlighting the growing pace of targeted therapeutics reaching patients through single-group and priority-review-style evidence packages.
-
RNAi IPO debut and public-market momentum
ADARx Pharmaceuticals priced its $446.3 million IPO, adding to 2026’s rapid biotech public-market pace. The RNAi specialist sold 26.25 million shares at $17 apiece and began trading on Nasdaq under the ticker ADRX. The company is advancing onvuzosiran for hereditary angioedema in Phase 3, while other RNAi candidates—including agazisiran for kidney diseases, geographic atrophy, and paroxysmal nocturnal hemoglobinuria—sit across mid-stage programs. ADARx also received a boost via a private stock sale to partner AbbVie. The listing underscores sustained investor appetite for RNA platforms that can expand beyond liver delivery and potentially serve chronic, systemic targets if efficacy and dosing durability hold up in later-stage studies.
-
Big dealmaking: Lilly expands China reach with InnoCare pact
Eli Lilly signed a discovery-stage collaboration with Beijing-based InnoCare Pharma, a deal valued at up to $3.35 billion. The partnership is designed to identify and advance compounds against as many as five undisclosed targets addressing unmet needs. Under the agreement, Lilly gains rights to develop and commercialize resulting candidates, with up to $100 million in upfront and near-term payments and up to $3.25 billion in development and milestone payments plus royalties. The structure fits Lilly’s broader playbook of sourcing innovation from China to replenish pipeline areas. The move further intensifies competition among global pharma to secure early-stage discovery access, with large milestone-heavy structures becoming a standard mechanism to balance early learning with long-term commercialization options.
-
CAR T in rare autoimmune disease: Kyverna gains durable signal
Kyverna Therapeutics reported one-year results supporting its FDA submission pathway for an autoimmune CAR-T program in stiff person syndrome. The data add to the durability narrative for rare autoimmune disorders where long-term remission is the key clinical goal. The company’s updates come as regulators continue to evaluate whether rare-disease efficacy evidence, once established, can translate into durable benefit sufficient for filing and approval. For competitors and partners, the main takeaway is the emphasis on persistence of response and safety characterization over multiple time horizons, rather than short-term response alone.
-
Chromatography and bioprocessing scale-up via SFC partnerships
Thar Process partnered with ExtrateX to bring prep-to-process-scale supercritical fluid chromatography (SFC) systems to Europe. The arrangement pairs Thar’s Isolator SFC platform for high-resolution separation with ExtrateX’s European footprint and scale-up process expertise. ExtrateX will handle sales, technical installation, maintenance, and training starting Jan. 1, 2027, positioning the partner channel for pharmaceutical and biotech purification use cases, including peptides and bioprocessing-derived products. The deal matters for downstream and CMC teams because supercritical CO2-based workflows increasingly compete on speed, efficiency, and sustainability—especially as biologics and peptide modalities demand more specialized separations.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.